46004-37-9

Basic information

• Product Name: Methyl 4-amino-2-chlorobenzoate
• Synonyms: methyl 4-amino-2-chlorobenzoate(SALTDATA: FREE);Methyl 4-amino-2-chlorobenzoate 2-Chioro-4-aminobenzoic acid methyl ester;METHYL 4-AMINO-2-CHLOROBENZOATE;2-chioro-4-aminobenzoic acid methyl ester;4-AMINO-2-CHLORO-BENZOIC ACID METHYL ESTER;AKOS BB-3102;2-chloro-4-amino benzoic acid methyl ester;Methyl 2-Chloro-4-Aminobenzoate
• CAS NO: 46004-37-9
• Molecular Formula: C₈H₈ClNO₂
• Molecular Weight: 185.61
• Product Categories: Phenylacetic acid;Miscellaneous;Benzenes;Aromatic Esters
• Mol File: 46004-37-9.mol

Chemical Properties

• Melting Point: 112-114°C
• Boiling Point: 334.207 °C at 760 mmHg
• Flash Point: 155.923 °C
• Appearance: /
• Density: 1.311 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Chloroform
• PKA: 1.41±0.10(Predicted)
• CAS DataBase Reference: Methyl 4-amino-2-chlorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-amino-2-chlorobenzoate(46004-37-9)
• EPA Substance Registry System: Methyl 4-amino-2-chlorobenzoate(46004-37-9)

Safety Data

• Hazardous Substances Data: 46004-37-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-amino-2-chlorobenzoate is used as a reagent for the synthesis of selective Liver X Receptor (LXR) agonists. These agonists are designed to increase High-Density Lipoprotein (HDL) levels and promote reverse cholesterol transport in mice, which can potentially lead to the development of novel treatments for dyslipidemia and related cardiovascular conditions.

InChI:InChI=1/C8H8ClNO2/c1-12-8(11)6-3-2-5(10)4-7(6)9/h2-4H,10H2,1H3

Upstream product

• 67-56-1 methanol 
• 2457-76-3 4-amino-2-chlorobenzoic acid 
• 99-60-5 2-chloro-4-nitrobenzoic acid 
• 77-78-1 dimethyl sulfate 
• 75-36-5 acetyl chloride 
• 7073-36-1 2-chloro-4-nitrobenzoyl chloride 
• 13324-11-3 methyl 2-chloro-4-nitrobenzoate 
• 38667-55-9 4-Acetylamino-2-chlorobenzoic acid 

Downstream Products

• 103859-12-7 4-amino-2-chloro-benzoic acid-(2-dimethylamino-ethyl ester) 
• 88-06-2 2,4,6-Trichlorophenol 
• 935676-14-5 methyl 4-amino-2-chloro-3-iodo-benzoate 
• 256935-85-0 methyl 4-amino-2-chloro-5-iodo-benzoate 
• 911313-97-8 Methyl 2-chloro-4-(3-ethoxycarbonylpropylamino)benzoate 
• 868406-71-7 methyl 4-amino-5-bromo-2-chlorobenzoate 
• 232275-86-4 methyl 4-(N,N-dimethylsulfamoyl)amino-2-chlorobenzoate 
• 260968-88-5 N-[4-(Carbomethoxy)-3-chlorophenyl] 4-fluorobenzenesulfonamide 
• 98592-34-8 2-chloro-4-cyano benzoic acid methyl ester 
• 158579-73-8 2-chloro-4-(N-methylsulphonylamino)benzoic acid 
• 53250-84-3 4-(aminosulfonyl)-2-chlorobenzoic acid 

Relevant articles and documents

Synthesis of a coronene analogue containing an amide bond by Pd-mediated intramolecular C[sbnd]C bond formation of 2-halogenated 4-(alkylamino)benzoic acid cyclic trimer

A coronene analogue containing amide linkage was synthesized from a halogenated cyclic triamide by palladium-mediated intramolecular C[sbnd]C bond formation. The cyclic triamide was formed from the condensation of 2-chloro-4-(isobutylamino)benzoic acid in

NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA

The present invention relates to compounds having a structure of general formula (I), processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in humans and warm-blooded animals.

PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Piperidine compounds of the Formular: (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R 1, R 2, R 3, L, R 4, L 1, Q and R 5 are as defined herein. The compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

Method for preparing halogenated aniline from halogenated nitrobenzene through catalytic hydrogenation

The invention discloses a method for preparing halogenated aniline from halogenated nitrobenzene through catalytic hydrogenation. The method comprises the following steps: in a reaction kettle, performing liquid phase catalytic hydrogenation reaction to halogenated nitrobenzene under the action of a sulfur-doped carbon material loaded noble metal catalyst, to obtain halogenated aniline shown in the formula (II), wherein the loading quantity of noble metal in the sulfur-doped carbon material loaded noble metal catalyst is 0.1-5wt%. In the method, the catalyst has good stability, the hydrogenation halogen removal side effect can be effectively inhibited under the condition of having no added halogen removal inhibitor, and the product selectivity is high.

CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Synthesis and trypanocidal activity of novel benzimidazole derivatives

The present work reports the synthesis and biological activity of a series of 14 benzimidazole derivatives designed to act on the enzyme triosephosphate isomerase of Trypanosoma cruzi (TcTIM). This enzyme is involved in the metabolism of glucose, the only source of energy for the parasite. In this study, we found four compounds that inhibit TcTIM moderately and lack inhibitory activity against human TIM (HsTIM). In vitro studies against T. cruzi epimastigotes showed two compounds that were more active than the reference drug nifurtimox, and these presented a low cytotoxic effect in mouse macrophages (J744 cell line).

TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY

The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treat

INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to indole carboxamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH A CO-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a CO-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or metabolic syndrome via inhibition of HDAC4.